Trials / Completed
CompletedNCT04480593
The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.
The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19: a Randomized, Open and Pilot Clinical Study.
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- D'Or Institute for Research and Education · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The COVID-19 pandemic is of grave concern due its impact on human health and on the economy. Propolis, a natural resin produced by bees from plant materials, has anti-inflammatory, immunomodulatory, anti-oxidant properties, and various aspects of the SARS-CoV-2 infection mechanism are potential targets for propolis compounds. Propolis components have inhibitory effects on the ACE2, TMPRSS2 and PAK1 signaling pathways; in addition, antiviral activity has been proven in vitro and in vivo. This is a pilot randomized study that aims to assess the impact of using Brazilian green propolis extract against the deleterious effects of the new coronavirus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brazilian Green Propolis Extract (EPP-AF) | Green propolis extract (EPP-AF) administered orally or via nasoenteral tube. |
| OTHER | Standard care | Standard treatment includes, as needed, supplemental oxygen (non-invasive and invasive), antibiotics or antivirals, corticosteroids, vasopressor support, renal replacement therapy and extracorporeal membrane oxygenation (ECMO). |
Timeline
- Start date
- 2020-06-02
- Primary completion
- 2020-08-30
- Completion
- 2020-08-30
- First posted
- 2020-07-21
- Last updated
- 2020-09-30
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT04480593. Inclusion in this directory is not an endorsement.